- Huchembio(CEO): HuChemBio has been founded to develop the first-in-class drugs essential for numerous patients who are suffering from diseases.
The existing first-in-class drug development involve numbers of problems including a huge investment,
high development failure rate, and long development period.
HuchemBio uses its SHADD system to gradually solve the problems of first-class new drug development in a short period of time and continuously discovers first-class new drug candidates to become a leading global new drug development company.
- Selective and differentiated drug development(stat3 inhibitor:Highly selective about stat familiy, High activity and low cytotoxicity. Develop treatments for inflammation and autoimmune diseases due to low cytotoxicity.
- Huchembio Business model: New drug development(License Out, Collaborative Research, Investment),
CRO(Drug Design/Synthetic Design and Synthesis/Collaborative Research), Sales of chiral reagents and APIs.
Company Details
- Founded
- 2021
- Address
- Room 807, Golden I-Tower, 570-6 Don, Hwaseong-Si,gy 18469,korea, Republic Of
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- http://www.huchembio.com
- Keywords
- Medichem, Drug Design, small molecular, Stat3, NFkB, Autoimmune, Resistant Cancer, Chiral synthesis, Process Chemistry, Hif, Atopy, Osteoporosis, Pulmonary inflammation, LOOPS, Rheumatoid Arthritis.
- HQ
- Hwaseong-si, Gy
- Competitors
- J Mackem Co., Ltd, Myst Enterprise, Skinpost Korea, DOHBIO.
Huchembio Questions
Huchembio's website is http://www.huchembio.com
Huchembio's LinkedIn profile is https://kr.linkedin.com/company/huchembio
Huchembio's industry is
Pharmaceutical Manufacturing
Huchembio's categories are Pharmaceutical Manufacturing
Huchembio's founding year is 2021
